Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
– In 2 nd line subjects (n=10) Annamycin in combination with Cytarabine (AnnAraC) achieved an estimated median overall survival (mOS) of 6 months and increasing plus 5 CR's (50%) and 6 CRc's (60%) – Recruitment increased to 22 subjects and CRc's in all subjects evaluable for efficacy (n=20) was 45% – Annamycin continues to demonstrate no cardiotoxicity – Data presented at European Hematology Association (EHA) 2024 Hybrid Congress and Company KOL Meeting in Madrid HOUSTON June 14, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported additional efficacy findings from the Company's ongoing Phase 1B /2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of su
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialPR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin to Present at the Virtual Investor Pitch ConferencePR Newswire
- Moleculin to Participate in the Virtual Investor Lunch Break Series [Yahoo! Finance]Yahoo! Finance
MBRX
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- MBRX's page on the SEC website